National Health Investors Price Target Raised to $78.00/Share From $65.00 by Truist Securities
National Health Investors Analyst Ratings
Deutsche Bank Maintains National Health Investors Inc(NHI.US) With Buy Rating, Raises Target Price to $90
Deutsche Bank Raises Price Target on National Health Investors to $90 From $69, Keeps Buy Rating
Wells Fargo Maintains National Health Investors Inc(NHI.US) With Buy Rating, Raises Target Price to $81
KeyBanc Initiates National Health Investors Inc(NHI.US) With Hold Rating
Buy Rating Justified by National Health Investors' Strong Q2 Financials and Growth Prospects
Analysts Offer Insights on Real Estate Companies: National Health Investors (NHI) and Global Net Lease (GNL)
BMO Capital Maintains National Health Investors Inc(NHI.US) With Buy Rating, Raises Target Price to $80
Analysts Offer Insights on Real Estate Companies: National Health Investors (NHI) and Postal Realty (PSTL)
National Health Investors Analyst Ratings
Truist Securities Adjusts Price Target on National Health Investors to $65 From $58, Maintains Hold Rating
National Health Investors Analyst Ratings
Wells Fargo Reaffirms Their Buy Rating on National Health Investors (NHI)
Analysts Offer Insights on Real Estate Companies: National Health Investors (NHI), Realty Income (O) and Alexander's (ALX)
Truist Financial Remains a Hold on National Health Investors (NHI)
National Health Investors Analyst Ratings
National Health Investors Analyst Ratings
National Health Investors Analyst Ratings
Optimistic Buy Rating for National Health Investors on Strong SHOP Performance and Strategic Acquisitions